Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Long-term Debt
Borrowings due after more than one year.
Entera Bio Ltd.NASDAQ: ENTX
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt remains negative
Q1 FY2026 long-term debt was $263K, compared with $0 a year earlier.
Context
- Long-term debt amounted to 2.0% of total assets at the end of Q1 FY2026, up 2.0 pp from a year earlier.
- Long-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 260K USD
- Year-over-year change
- —
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 260K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Long-term Debt vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 long-term debt of $263K is the 6th highest of the 10 companies compared; the peer median is $507K.
- Long-term debt amounts to 2.0% of total assets for ENTX, versus a peer median of 0.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $153.99M | +368.8% | +138.0% | 82.6% | |
IRDOpus Genetics, Inc. | Mar 2026 | $25.93M | — | — | 38.8% |
| Mar 2026 | $20.38M | — | — | 7.5% | |
| Mar 2026 | $16.92M | -41.1% | — | 12.7% | |
| Mar 2026 | $507K | — | — | 0.9% | |
| Mar 2026 | $263K | — | — | 2.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Apr 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ENTX) | $507K | +163.8% | +138.0% | 0.9% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.